Tramadol in the Peloton: Cycling's Medical Ban and Nairo Quintana's Disqualification

Timeline

1. 2017WADA monitoring finds tramadol in 4.4 percent of in-competition tests on cyclists; cyclists account for 68 percent of tramadol-positive urine samples across 35 Olympic sports.
2. Jun 2018The UCI Management Committee decides to ban in-competition tramadol use.
3. Mar 1, 2019The UCI ban takes effect under its Medical Rules, enforced with dried blood spot tests.
4. Jul 8 and 13, 2022Samples from Nairo Quintana at the Tour de France contain tramadol and its two main metabolites.
5. Aug 17, 2022The UCI disqualifies Quintana from the 2022 Tour, where he finished sixth, and fines him CHF 5,000.
6. Sep 23, 2022WADA's Executive Committee endorses prohibiting tramadol in competition from 2024.
7. Nov 3, 2022CAS dismisses Quintana's appeal.
8. Jun 5, 2023CAS publishes its reasoned award, holding the tramadol control is a medical measure with no B-sample right.
9. Oct 28, 2023Quintana signs a one-year deal with Movistar after a season without a team.
10. Jan 1, 2024Tramadol becomes prohibited in competition on WADA's list.

The ethical issues

• Paternalism: banning a legal painkiller to protect riders who might choose to take it.
• Safety of others: a drug that can cause drowsiness raises crash risk for the whole peloton.
• Jurisdiction: whether a federation may create a 'medical' offense outside the anti-doping system.
• Proportionality: disqualification and loss of a team contract without a doping ban.
• Culture of pain management: normalizing opioid use to keep racing.

Stakeholders

Stakeholder	Interests & obligations
Riders	Health, safety in the bunch and freedom to manage pain.
Nairo Quintana	His result, reputation and career.
Teams and team doctors	Rider welfare, results and compliance.
UCI	Rider safety and authority to regulate medical practice.
WADA	A coherent prohibited list and harmonized rules.
Race organizers and fans	Safe, credible racing.

The case

Nairo Quintana finished sixth at the 2022 Tour de France, his best Grand Tour result in years. A month later the result was gone. Two fingertip blood samples showed tramadol, a painkiller that was legal under the World Anti-Doping Code but banned by cycling’s governing body as a safety risk. Quintana was not suspended, because his offense was not a doping violation. He lost his result, a fine, and soon his team.^[2][6]

Background

Tramadol is a synthetic opioid painkiller. WADA had tracked it through its monitoring program, which watches substances that are not prohibited, and found heavy use in cycling. According to the UCI, the 2017 survey showed tramadol in 4.4 percent of in-competition tests on cyclists, and 68 percent of tramadol-positive urine samples across 35 Olympic sports came from cyclists.^[1]

The UCI pointed to two kinds of risk: side effects such as “nausea, drowsiness and loss of concentration (increasing the risk of race crashes),” and “gradual dependence on the substance with a risk of developing an addiction.” It also noted that tramadol is available on prescription but “freely available on the internet, which increases the risk of uncontrolled self-medication.”^[1]

The rules and governance

Normally, a substance is banned in Olympic sport by being placed on WADA’s Prohibited List, which requires meeting at least two of three criteria: performance enhancement, health risk and violation of the spirit of sport.^[5] Tramadol was not on the list. In June 2018, the UCI Management Committee decided to ban it anyway, through the UCI’s own Medical Rules rather than its anti-doping rules. The ban took effect on March 1, 2019, across all disciplines and categories, with the stated aim of “preserving the rider’s health and safety.”^[1]

Testing uses dried blood spots: a small amount of blood from the rider’s fingertip, collected in competition, often at the end of races. There is no threshold; any presence counts. Avoiding a test is treated as a positive. A first offense brings disqualification from the event and a CHF 5,000 fine for riders on UCI-registered teams; a second brings a five-month suspension, and a third nine months. Teams with two offenders in 12 months are fined, and can be suspended for further offenses. Because these are medical offenses, they “do not constitute Anti-doping Rule Violations.”^[1][2]

By 2022, samples were collected by the International Testing Agency, analyzed at a Geneva University laboratory, independently reviewed at the University of Lausanne, and then managed by the UCI Medical Director. At the 2022 Tour, 120 dried blood samples were collected for the tramadol program.^[2]

Quintana’s disqualification

Quintana, a Colombian climber, had won the 2014 Giro d’Italia and 2016 Vuelta a España and twice finished runner-up at the Tour de France. Riding for Arkéa-Samsic in 2022, he placed sixth overall.^[4][6] Samples he gave on July 8 and 13 revealed tramadol and its two main metabolites. On August 17, 2022, the UCI Medical Director disqualified him from the race and fined him CHF 5,000. As a first offense, the UCI said, he was “not declared ineligible and can therefore participate in competitions.”^[2][3]

Quintana said: “I am totally unaware of the use of this substance and I deny having used it in my career.”^[4]

The appeal

Quintana appealed to the Court of Arbitration for Sport on August 26, 2022, seeking annulment. After a hearing on October 12, the panel ruled on November 3. It “determined that the UCI’s in-competition ban on tramadol was for medical rather than doping reasons and was therefore within the UCI’s power and jurisdiction,” and was “comfortably satisfied that the scientific evidence showed that Nairo Quintana’s samples contained both tramadol and its two metabolites.” The appeal was dismissed.^[3]

The UCI said the decision “reinforces the validity of the tramadol ban in the UCI Medical Regulations in order to protect the health and safety of riders.”^[4]

Inside the award

The full reasoned award, issued on June 5, 2023, shows that Quintana attacked the system as well as his own result.^[7] His lawyers argued that the tramadol control “is clearly a doping control,” because samples were collected by the International Testing Agency, “an anti-doping organization.” In their view the UCI “can’t add any matter related with doping, it doesn’t matter if UCI says it is not a doping issue,” and only WADA could ban a substance.^[7] They listed the protections a doping case would have given him and this one did not. There was no B sample, which they called “a fundamental right for the athlete.” The laboratory was not WADA-accredited. The appeal period was 10 days instead of 30. And he had not been invited to give his side before the sanction.^[7] His expert, a forensic toxicologist, also argued that one of the two metabolites had not been properly identified. On the reported concentrations, the expert said, “it was unlikely that [the Rider] was under the influence of the drug during the competition.”^[7]

The panel rejected each point. The Medical Rules bound Quintana because he had agreed to them when he took out a licence, and the rule itself said riders “explicitly agree and acknowledge that tramadol is prohibited in-competition.”^[7] Federations, it said, “enjoy a margin of appreciation” on health and safety. The UCI was “legitimately entitled” to ban “a synthetic opioid analgesic that has dangerous side effects, including in particular, dizziness, and can be addictive.” The panel added that WADA had confirmed in writing that the Medical Rules “are not anti-doping rules.”^[7] Because the control was medical, “there is no free-standing abstract right to a B sample,” and no WADA-accredited laboratory was required. The panel held that any failure to hear Quintana first had been “cured by the de novo nature of the CAS hearing.”^[7] On the science, the panel accepted corrected figures for one metabolite. It found the other present at about 2.5 to 2.8 ng/mL, above the detection limit but below the level at which it could be quantified. It also found that the rider’s own expert accepted an intake 12 to 48 hours before the samples were taken after the seventh and eleventh stages.^[7] Under the rules, departures from the technical procedures do not invalidate a result unless they caused it. The sanctions were the fixed first-offence penalties: disqualification, the CHF 5,000 fine and the cost of the control. The award noted that “there is no challenge to the validity or proportionality of the sanctions.”^[7]

The award reveals a tension in the case. The ban was justified as a safety measure against riders impaired in the bunch. Yet the offence was the presence of the drug, with no threshold and no need to show impairment. Quintana’s expert’s view that he was probably not under its influence during the race therefore had no bearing on the result.^[1][7]

Aftermath

Arkéa-Samsic dropped Quintana after the disqualification, and he spent 2023 without a team, training in Europe. In October 2023, Movistar, the team where he had won his Grand Tours, signed him to a one-year deal. “It’s been such a tough year,” he said. “The sleepless nights, so many days of sacrifice.” Cyclingnews described him as the first cyclist punished for tramadol.^[6]

Meanwhile, on September 23, 2022, WADA’s Executive Committee endorsed adding tramadol to the Prohibited List in competition, effective January 1, 2024, with a delay to allow education. WADA said monitoring data “indicated significant use in sports,” that tramadol abuse carries risks of “physical dependence, opiate use disorder and overdoses,” and that WADA-funded research had “confirmed the potential for tramadol to enhance sports performance.” The UCI’s own guidance on the ban was marked as no longer in force from February 2024.^[1][5]

The core dilemma

The UCI acted to protect riders from a drug that WADA had not banned. That made it a pioneer, but also created an unusual offense: not doping, yet punished by disqualification. Quintana kept his eligibility but lost his result and his job. When should a sport restrict a legal medicine for safety, and how should it punish riders under such a rule?

Competing values

• Rider autonomy vs. protection: adults may choose painkillers, but opioids carry addiction risk.
• Individual choice vs. others’ safety: a drowsy rider endangers the whole bunch.
• Federation authority vs. harmonization: acting alone filled a gap but created a parallel system.
• Formal sanction vs. real consequences: “not a doping offense” still cost a career year.

Strongest arguments

For the UCI ban: data showed extensive use in cycling, the drug’s side effects plausibly raise crash risk for everyone, and addiction is a serious harm. Waiting for WADA would have left riders exposed for years. Fingertip testing made enforcement simple and minimally invasive.

Against, or for caution: tramadol is a legitimate medicine. Creating a separate offense outside the anti-doping system raised jurisdictional questions and placed riders under a different process with different safeguards. For a rider who denies use, losing a result and a contract without a doping finding sits uneasily between two systems.

On WADA’s later listing: it vindicated the UCI’s concern, but it also suggests the issue was always as much about performance as safety, as WADA’s own research indicated.

Applying the frameworks

Care ethics

Care ethics centers riders’ wellbeing and the relationships of responsibility around them. Teams and doctors owe riders pain management that does not risk addiction or crashes. A culture in which riders reach for opioids to finish races is a failure of care, and a ban is one way, though not the only way, to address it.

Utilitarian

A utilitarian would weigh reduced crashes and addiction against lost pain relief and the costs to sanctioned riders. If tramadol use was as widespread as the monitoring suggested, the safety benefits across the peloton could be substantial, even accounting for individual hardships.

Rights-based

A rights lens asks about bodily autonomy and due process. Riders have a right to make medical choices, but that right is limited when the choice endangers others in a shared race. Riders also have a right to clear rules and fair procedures, which is why the jurisdictional question CAS answered mattered.

Walk it through: the Simple Decision Model

1. Spot the issue. You are the UCI Medical Director in 2018 deciding whether to recommend a tramadol ban before WADA acts. Stakeholders include riders, teams, team doctors, race organizers, WADA and fans. The codes in play are the UCI Constitution and Medical Rules, the World Anti-Doping Code and rider health obligations.
2. Gather facts. How widespread is use? What evidence links it to crashes or addiction? Is reliable, minimally invasive testing available? Watch for the bias of assuming a widely used substance must be performance-enhancing, or harmless.
3. Test options. Options: (a) wait for WADA; (b) education only; (c) a medical ban with graduated sanctions. Weigh rider safety, autonomy and legal risk.
4. Check codes and law. Confirm the UCI’s authority to regulate on medical grounds and keep the rule distinct from anti-doping procedures. Ensure an appeal route.
5. Decide and document. Publish the evidence base and sanctions in advance.
6. Communicate and follow up. Educate riders and team doctors, provide guidance on alternative pain management and share data with WADA.

What’s settled and what’s contested

• Settled: the UCI ban from March 1, 2019; Quintana’s two positive samples, disqualification and fine; CAS’s ruling that the ban was a valid medical measure; and WADA’s in-competition prohibition from 2024.
• Contested: Quintana denies using tramadol; whether a medical rule should carry disqualification; and how far a federation should go in restricting legal medicines on paternalistic grounds.

Why this case matters

Sport often treats drugs as a question of cheating. The tramadol ban shows a federation regulating a drug mainly as a question of safety, and the complications that follow. It is a useful case for thinking about paternalism, shared risk, the limits of a governing body’s power and the real-world consequences of rules that are “not doping.”

Key terms

Paternalism (hard and soft)

Restricting someone’s choices for their own good. Hard paternalism overrides competent, informed adults; soft paternalism steps in when information or autonomy is compromised.

Consent and autonomy

Whether people have agreed freely and with full information, and whether their right to make their own choices is respected.

Non-maleficence

The duty to avoid causing harm, often paired with care ethics when setting safety rules.

Duty of care

The responsibility of coaches, organizations and institutions to protect the health, safety and well-being of those in their charge. It is not a license for total control.

Rules vs. spirit of the game

Rules are the written minimum; the spirit is the fairness and respect the rules exist to protect. Rules set the floor; spirit sets the ceiling.

Due process

Fair procedures before a sanction: notice, a chance to respond, an impartial decision-maker and a right of appeal.

Definitions from the Ethics Cases glossary.

Discussion questions

1. Is the UCI's tramadol ban justified paternalism? Does the risk to other riders change your answer?
2. Should a rule violation that is 'not doping' cost a rider his race result and, in practice, his team contract?
3. Was it better for cycling to act alone in 2019, or should it have waited for WADA to list the drug?
4. Quintana denied using tramadol, yet the result stood. What standard of proof should apply to medical-rule offenses?
5. How should sport address the wider culture of pain management that leads riders to use opioids?

Sources

1. [Not in force from 05.02.24] Tramadol ban: All you need to know — UCI
2. UCI statement concerning Nairo Quintana Rojas — UCI
3. The CAS dismisses the appeal filed by Nairo Quintana (Media Release) — Court of Arbitration for Sport
4. Nairo Quintana's appeal against Tour de France disqualification dismissed — BBC Sport
5. WADA's 2024 Prohibited List now in force — World Anti-Doping Agency
6. Nairo Quintana rejoins Movistar in surprise return to WorldTour — Cyclingnews
7. Nairo Alexander Quintana Rojas v. UCI, CAS 2022/A/9113, Arbitral Award (June 5, 2023) — Court of Arbitration for Sport